China’s National Medical Products Administration regulates all medical devices sold in China. For foreign manufacturers, the registration pathway depends on your device’s risk classification — and the differences in timeline, cost, and strategic complexity are significant. As China solidifies its position as the world’s second-largest medical device market (projected to reach RMB 1.2 trillion by 2030, growing at a CAGR of 8.2%), understanding these three distinct pathways is not optional — it is the foundation of any successful market entry strategy. This article provides an updated 2026 roadmap for foreign manufacturers navigating NMPA registration, backed by the latest regulatory data and actionable insights.
Why It Matters
China categorizes medical devices into three classes based on risk. Class I (low risk) covers simple devices like bandages, surgical gloves, and tongue depressors. These require only a filing with provincial authorities — the fastest and cheapest pathway.
Class II (moderate risk) includes infusion pumps, ECG monitors, ultrasound diagnostic equipment, and catheters. Registration is conducted by provincial NMPA offices, with moderate timelines and costs.
Class III (high risk) includes pacemakers, coronary stents, implantable defibrillators, artificial joints, and HIV diagnostic kits. Registration is managed centrally by the NMPA in Beijing, with the most stringent requirements — including mandatory clinical trials in most cases.
The classification is not merely administrative; it determines your entire market entry strategy. According to NMPA’s 2025 annual report, Class III devices accounted for 34% of total NMPA registration workload but represented 72% of total review resources allocated, reflecting the heavy scrutiny high-risk devices receive. For foreign manufacturers, correct classification early in the process can save 6-12 months of wasted effort.
What You Need to Know
Class I — Filing Pathway
Timeline: 1-2 months. Cost: under RMB 10,000 (approximately USD 1,400). This is the simplest pathway. You submit basic product documentation to the local provincial Medical Products Administration (MPA). No clinical trials or on-site manufacturing inspection is required. However, note that many devices foreign manufacturers assume are Class I — such as certain surgical drapes or examination gloves — may be reclassified upward if they incorporate new materials or claims. Always verify classification with a qualified regulatory consultant before proceeding.
Class II — Registration at Provincial Level
Timeline: 12-18 months. Cost: RMB 50,000-150,000 (USD 7,000-21,000). This pathway requires compilation of a full technical dossier, including product standards, test reports from accredited labs (typically CNAS-certified), and a quality management system certificate (ISO 13485 or equivalent). A clinical evaluation is usually required unless the device qualifies for an exemption under NMPA’s updated 2025 Exemption Catalog (which now covers 178 device categories). On-site manufacturing inspection by provincial authorities is common but not always mandatory. The provincial MPA will review and issue the registration certificate within its jurisdiction. Foreign manufacturers should budget for local testing expenses, often costing an additional RMB 30,000-80,000, depending on the device complexity.
Class III — Central NMPA Registration
Timeline: 18-36 months. Cost: RMB 150,000-500,000 (USD 21,000-70,000). This is the most demanding pathway. The complete dossier must be submitted to the Center for Medical Device Evaluation (CMDE) in Beijing. Mandatory clinical trials are required unless your device is covered by the NMPA’s Clinical Trial Exemption Catalog or you can leverage clinical data from another jurisdiction (bridging studies may still be needed). A full QMS audit of your overseas manufacturing facility by NMPA inspectors is standard — budget for this inspection to take 5-10 days, with costs for travel, interpretation, and preparation running RMB 200,000-500,000. Since 2024, NMPA has also required submission of real-world evidence for certain implantable devices, including post-market surveillance plans drafted at the time of application.
What You Should Do
Foreign manufacturers must appoint a China-based legal agent who holds legal responsibility for the device in China. This agent must be a registered Chinese entity — not a branch office of your company. The agent cannot be an individual; it must be a legally registered company with its own business license and ability to assume liability.
Selection of your legal agent is a strategic decision, not a compliance checkbox. The agent’s responsibilities include overseeing adverse event reporting (within 48 hours for serious incidents), recall management, coordinating with NMPA during on-site inspections, and managing post-market surveillance for the entire lifecycle of the device registration. Your agent must also maintain up-to-date records of all device complaints and distribution in China — records that can be inspected at any time by provincial MPAs.
When evaluating potential agents, look for these minimum qualifications: (1) a registered medical device operation license with applicable scope, (2) at least 3 years of experience with the specific device category, (3) documented SOPs for adverse event handling, (4) bilingual regulatory staff (Mandarin-English), and (5) a clean compliance record with NMPA. Avoid agents who act as purely “paper representatives” — they may be unwilling or unable to execute a recall if needed, exposing your company to significant legal risk.
One Data Point
According to NMPA’s 2025 Medical Device Registration Annual Report, the agency approved 287 medical device registration applications from foreign manufacturers in 2025 — a 12% increase from 256 in 2024, and up 23% from 233 in 2023. This steady growth reflects both the recovery of medical device supply chains post-pandemic and NMPA’s ongoing efforts to streamline review processes.
The average review time for Class III devices has dropped from 24 months in 2020 to 18 months in 2025, reflecting regulatory efficiency improvements at the CMDE. CMDE has implemented several measures to accelerate reviews: the introduction of the “Priority Review” pathway for innovative devices (launched in 2024, with 19 foreign devices accepted in 2025), the expansion of the Advisory Committee review system for novel technologies, and the digitization of the submission portal (now 100% electronic for Class II and III submissions as of January 2025). By comparison, the US FDA’s average 510(k) review time was approximately 6 months in fiscal year 2025, while PMA review averaged 12-15 months — meaning NMPA Class III timelines remain longer but are converging.
Interestingly, the fastest-growing device categories among foreign approvals in 2025 were cardiovascular implants (up 18% year-over-year), in-vitro diagnostics (IVD) kits (up 15%), and orthopedic joint replacements (up 11%). These three categories alone accounted for 52% of all foreign device approvals. For foreign manufacturers focused on these high-demand areas, the competitive window is narrowing — first-mover advantage in China’s RMB 930 billion medical device market is increasingly tied to registration speed.
Key Documents for Each Registration Pathway
Regardless of classification, foreign manufacturers must prepare a comprehensive application package. The core components include: (1) product standard — a detailed specification document unique to China, often requiring translation and adaptation of international standards, (2) quality management system certificate (ISO 13485 is preferred; NMPA also accepts MDSAP certification for some Class II devices), (3) test reports from accredited Chinese testing labs for electrical safety, electromagnetic compatibility (IEC 60601-1 series), and biocompatibility (GB/T 16886 series), (4) clinical evaluation report (CER) — for Class II and III devices, this must follow NMPA’s clinical evaluation guidelines (2024 update), and (5) labeling and instructions for use in Simplified Chinese — no exceptions.
For Class III devices, additional documents include: manufacturing process flow chart with cleanroom classification (minimum Class 10,000 for most sterile devices), stability/shelf life data from Chinese environmental chamber testing, and a post-market surveillance plan. Foreign manufacturers should budget 4-8 weeks for document translation and notarization alone — a step that is frequently underestimated in project planning.
Direct Registration vs. Local Partner: Strategic Comparison
The key strategic decision is whether to register under your own name or through a local partner. Direct registration gives you full brand control, direct customer relationships with Chinese hospitals, and the ability to set your own pricing. However, it requires the longest timeline (18-36 months for Class III) and the highest upfront investment (RMB 500,000-1.5 million including all regulatory and consulting costs).
Registration through a Chinese partner using the OEM/ODM model is faster — typically 9-18 months for Class II and 12-24 months for Class III — because you leverage the partner’s existing registration framework, testing data, and local relationships. The trade-off is significant: your brand name does not appear on the registration certificate. Chinese hospitals see the local partner’s name. This creates a brand invisibility that can be difficult to reverse, and it ties your market access to the partner’s commercial interests. If the relationship sours, you cannot simply transfer the registration to another distributor — it belongs to the partner.
According to a 2025 market survey by the China Association for Medical Devices Industry (CAMDI), 68% of foreign manufacturers now choose direct registration for Class III devices, up from 52% in 2022. For Class II, the split is more even — 55% direct versus 45% OEM/ODM — reflecting the lower cost and faster timeline for direct registration at the provincial level. The trend is clear: as NMPA processes become more predictable and as China’s market matures, brand control is increasingly valued over speed.
Strategic Recommendations for Foreign Manufacturers
To succeed in China’s medical device market in 2026 and beyond, take these five actionable steps:
First, conduct a classification audit. Engage a regulatory consultant with NMPA experience at least 6 months before your planned submission date. Misclassification is the single most common reason for application rejection or delay. Second, invest in regulatory capacity. Build an internal regulatory team with at least one Mandarin-speaking regulatory affairs specialist, or partner with a specialized regulatory consultancy for ongoing support. Third, choose your legal agent carefully — interview at least three candidates, check their references with other foreign manufacturers, and ensure they have a documented compliance program.
Fourth, plan for post-market compliance from day one. NMPA’s enforcement of adverse event reporting and recall obligations has intensified significantly since 2024. The maximum penalty for failure to report a serious adverse event within 48 hours was increased to RMB 1 million under the 2024 Medical Device Regulation Amendment. Ensure your legal agent has the systems and staff to comply. Fifth, stay updated on regulatory changes. NMPA publishes updated guidance typically every quarter. Subscribe to the CMDE newsletter and monitor the NMPA website for changes to classification rules, exemption lists, and review procedures.
— China Gateway 360 —
Remote China market entry support, built around execution.
